Tags: Drug.
Motavizumab (proposed INN trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009 it is undergoing Phase II and III clinical trials.In June 2010 the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune’s request for licensure of Motavizumab in a 14 to 3 decision.